Back
Full-text
Journal article

The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus.

  • Passweg JR EBMT Activity Survey Office, Hematology, Department of Medicine, University Hospital, Basel, Switzerland. jakob.passweg@usb.ch.
  • Baldomero H EBMT Activity Survey Office, Hematology, Department of Medicine, University Hospital, Basel, Switzerland.
  • Chabannon C Institut Paoli Calmettes & Inserm CBT-1409, Centres d'Investigations Cliniques en Biothérapies, Marseille, France.
  • Basak GW Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
  • Corbacioglu S Pediatric Hematology, Oncology and Stem Cell Transplantation Department, Children's Hospital, Regensburg, Germany.
  • Duarte R Servicio de Hematologia y Hemoterapia, Hospital Universitario Puerta de Hierro, Madrid, Spain.
  • Dolstra H Laboratory of Hematology, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Lankester AC Willem-Alexander Children's Hospital, Department of Pediatrics, Leiden University Medical Centre Leiden, Leiden, The Netherlands.
  • Mohty M Department of Hematology, Hospital Saint Antoine, Paris, France.
  • Montoto S St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
  • Peffault de Latour R BMT Unit, Department of Hematology, Hospital St. Louis, Paris, France.
  • Snowden JA Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Styczynski J Department of Pediatric Hematology and Oncology, University Hospital, Collegium Medicum UMK, Bydgoszcz, Poland.
  • Yakoub-Agha I CHU de Lille, LIRIC, INSERM U995, Université de Lille, 59000, Lille, France.
  • Kröger N Department of Stem Cell Transplantation, University Hospital Eppendorf, Hamburg, Germany.
Show more…
  • 2020-02-19
Published in:
  • Bone marrow transplantation. - 2020
Transplantation
Hematology
English Hematopoietic-cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number of transplants performed in Europe and associated countries continues to rise with 47,468 HCT in 42,901 patients [19,630 allogeneic (41%) and 27,838 autologous (59%)] reported by 701 centers in 50 countries in 2018. Main indications were myeloid malignancies 10,679 (25%; 97% allogeneic), lymphoid malignancies 27,318 (64%; 20% allogeneic), solid tumors 1625 (4%; 2.9% allogeneic), and nonmalignant disorders 3063 (7%; 81% allogeneic). This year's analysis focuses on cellular therapies with the marked growth in CAR T-cell therapies from 151 in 2017 to 301 patients reported in 2018. Other cellular therapy numbers show less significant changes. Important trends in HCT include a 49% increase in allogeneic HCT for chronic phase CML (although transplant numbers remain low) and a 24% increase in aplastic anemia. In autologous HCT, there is an ongoing increase in autoimmune diseases (by 19%), predominantly due to activity in multiple sclerosis. This annual report reflects current activity and highlights important trends, useful for health care planning.
Language
  • English
Open access status
hybrid
Identifiers
Persistent URL
https://sonar.ch/global/documents/189347
Statistics
Document views: 99 File downloads:
  • Full-text: 0